Relistor (Methylnaltrexone Bromide) Patent Expiration, LOE Window & CMS Spending

Relistor (Methylnaltrexone Bromide) by Bausch Health: FDA Orange Book LOE 2030-12-31, 0 AB generics, $193.1M 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN021964 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-12-31
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$193.1M
2024 Medicare Part D Spend$134.6M
2024 Medicaid Spend$58.6M
Reported Wholesale Price Change (CA SB 17)24 WAC filings (max 33.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.